What it isTricyclic antidepressant that is also a D2 antagonist; depression.
Why it mattersIt combines antidepressant and antipsychotic action in one molecule, which occasionally suits psychotic depression.
What it changes⚑ The D2 blockade brings extrapyramidal effects, tardive dyskinesia and neuroleptic malignant syndrome — unexpected from a tricyclic. It is the metabolite of loxapine.
BOXED WARNING Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with antidepressant use.
FDA dosing
Population
Start
Target
Max
Depression
Adult
50 mg BID-TID
200-300 mg/day
400 mg/day (600 mg/day in hospitalized refractory patients)
Depression
Elderly
25 mg BID-TID
100-150 mg/day
300 mg/day
Titration Maintain 300 mg/day for at least 2 weeks before increasing above 300 mg/day.
Renal Undefined
Hepatic Undefined
Instructions
Doses over 300 mg/day must be given in divided doses
When effective dose is established, may give as single dose (not exceeding 300 mg) at bedtime
Contraindications
MAOIs (concurrently or within 14 days) due to risk of hyperpyretic crises, severe convulsions, and death
Acute recovery phase following myocardial infarction
Cautions
Tardive dyskinesia
Neuroleptic malignant syndrome
Seizures
Sedative and anticholinergic effects
Adverse reactions
Drowsiness
Dry mouth
Constipation
Blurred vision
Pregnancy No teratogenic effect in animals; embryotoxicity and fetotoxic effects (intrauterine death, stillbirth, decreased birth weight) seen in animals at 3-10x human dose.
Lactation Undefined
⚠ BOXED WARNING
Suicidal thoughts and behaviors in patients under 25
“Ammo mocks A send-in” Tricycle symbol → tricyclic antidepressant (TCA) Spooky mascot → D2-blocking like an antipsychotic He’s ascendin’ and holding a “send-in”